EU: scPharmaceuticals (SCPH) Stock Has Just Had Its Buy Rating Reiterated by Jefferies. Shares now Have a $12 Target

June 14, 2018 - By Robert Crowder

scPharmaceuticals (SCPH) Rating Reaffirmed

Equity analysts at Jefferies now has a $12 TP on scPharmaceuticals (SCPH). Jefferies and their recent TP indicates a potential upside of 101.68 % from the company’s last stock close. The rating has been revealed to investors in an analyst report on Thursday, 14 June.

scPharmaceuticals Inc. (NASDAQ:SCPH) Ratings Coverage

Among 2 analysts covering scPharmaceuticals Inc (SCPH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. scPharmaceuticals Inc has $26.0 highest and $2000 lowest target. $23’s average target is 286.55% above currents $5.95 stock price. scPharmaceuticals Inc had 2 analyst reports since March 21, 2018 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Wednesday, March 21 report. The stock of scPharmaceuticals Inc. (NASDAQ:SCPH) has “Buy” rating given on Wednesday, April 4 by Leerink Swann.

The stock increased 0.34% or $0.02 during the last trading session, reaching $5.95. About 227,359 shares traded or 36.67% up from the average. scPharmaceuticals Inc. (SCPH) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await scPharmaceuticals Inc. (NASDAQ:SCPH) to report earnings on August, 6. After $-0.47 actual earnings per share reported by scPharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 34.04 % negative EPS growth.

scPharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company has market cap of $110.33 million. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting. in March 2014. It currently has negative earnings.

More notable recent scPharmaceuticals Inc. (NASDAQ:SCPH) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: J.Jill Climbs On Earnings Beat; Scpharmaceuticals Shares Fall” on May 31, 2018, also Nasdaq.com with their article: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” published on June 13, 2018, Nasdaq.com published: “Mid-Morning Market Update: Markets Edge Higher; Korn/Ferry Beats Q4 Views” on June 13, 2018. More interesting news about scPharmaceuticals Inc. (NASDAQ:SCPH) were released by: Benzinga.com and their article: “31 Stocks Moving In Wednesday’s Mid-Day Session” published on June 13, 2018 as well as Benzinga.com‘s news article titled: “38 Biggest Movers From Yesterday” with publication date: June 14, 2018.

scPharmaceuticals Inc. (NASDAQ:SCPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: